A Phase 3 interventional study of 10% IGIV in Primary Immune Deficiency Diseases (PIDD), sponsored by Evolve Biologics. Completed at 12 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Evolve Biologics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2017, is one of 18 in phase 3, and was the 21st registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 21 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 26 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 27 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Evolve Biologics as lead sponsor.
Evolve Biologics has 1 study filed under Primary Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of subjects with primary immune deficiency diseases (PIDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions. The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo.
Biological: 10% IGIV
300-900 mg/kg
Also known as: Human Immunoglobulin
Mean Acute Serious Bacterial Infection (SBI) Rate
The primary efficacy endpoint was the rate of acute SBI (pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, visceral abscess) per participant during the 12-month study observation period
Time frame: 1 year
Immunoglobulin G (IgG) Trough Concentration
The average serum total IgG trough concentration
Time frame: Up to 1 year per participant
Days Unable to Perform Daily Activities
The number of days out of work/school/daycare or unable to perform normal daily activities due to infections
Time frame: Up to 1 year per participant
Therapeutic IgG Levels
Number of participants with maintenance of stable IgG levels
Time frame: Up to 1 year per participant
A total of 63 patients were enrolled between September 2017 and August 2020 at 13 sites across the United States and Canada.
| Milestone | Adults | Pediatrics |
|---|---|---|
| Started | 48 | 15 |
| Completed | 42 | 15 |
| Not completed | 6 | 0 |
The primary efficacy endpoint was the rate of acute SBI (pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, visceral abscess) per participant during the 12-month study observation period
| Percentage | Adults | Pediatrics |
|---|---|---|
| Mean Acute Serious Bacterial Infection (SBI) Rate | 0 | 0 |
The average serum total IgG trough concentration
| mg/mL | Adults | Pediatrics |
|---|---|---|
| Infusion 1 (Pre-dose) | 974.3 ± 175.6 | 925.5 ± 239.4 |
| Infusion 2 | 977.8 ± 177.0 | 951.0 ± 213.6 |
| Infusion 3 | 975.8 ± 204.9 | 996.0 ± 212.0 |
| Infusion 4 | 963.1 ± 182.8 | 1041.7 ± 230.9 |
| Infusion 5 | 976.2 ± 194.8 | 1027.9 ± 217.3 |
| Infusion 6 | 951.9 ± 193.0 | 1071.0 ± 205.3 |
| Infusion 7 | 980.0 ± 185.1 | 1011.3 ± 209.4 |
| Infusion 8 | 967.5 ± 200.4 | 1039.6 ± 258.2 |
| Infusion 9 | 970.4 ± 200.7 | 1077.7 ± 236.3 |
| Infusion 10 | 992.6 ± 203.7 | 1047.3 ± 193.8 |
| Infusion 11 | 999.2 ± 197.3 | 1075.8 ± 230.4 |
| Infusion 12 | 1016.0 ± 215.7 | 1054.1 ± 201.3 |
| Infusion 13 | 1007.5 ± 189.5 | 1061.3 ± 241.1 |
| Infusion 14 | 1090.1 ± 266.9 | 1198.9 ± 183.9 |
| Infusion 15 | 1057.4 ± 223.5 | 1154.9 ± 223.4 |
| Infusion 16 | 1092.4 ± 261.9 | 1117.3 ± 205.5 |
| Infusion 17 | 1139.6 ± 241.5 | 1171.6 ± 230.1 |
| Safety Follow-Up | 1010.8 ± 208.1 | 1110.1 ± 322.0 |
The number of days out of work/school/daycare or unable to perform normal daily activities due to infections
| Days | Adults | Pediatrics |
|---|---|---|
| Days Unable to Perform Daily Activities | 6.0 ± 9.6 | 8.1 ± 11.6 |
Number of participants with maintenance of stable IgG levels
| Participants | Adults | Pediatrics |
|---|---|---|
| Therapeutic IgG Levels | 48 | 15 |
Collected over From enrollment to end of follow-up at 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults | 0/48 (0%) | 4/48 (8.3%) | 44/48 (91.7%) |
| Pediatrics | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Event | Adults | Pediatrics |
|---|---|---|
| PneumoniaInfections and infestations | 1/48 | 0/15 |
| PyelonephritisInfections and infestations | 1/48 | 0/15 |
| Viral infectionInfections and infestations | 1/48 | 0/15 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/48 | 0/15 |
| Event | Adults | Pediatrics |
|---|---|---|
| HeadacheNervous system disorders | 19/48 | 9/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/48 | 7/15 |
| VomitingGastrointestinal disorders | 4/48 | 6/15 |
| NauseaGastrointestinal disorders | 5/48 | 5/15 |
| PyrexiaGeneral disorders | 7/48 | 5/15 |
| NasopharyngitisInfections and infestations | 7/48 | 5/15 |
| FatigueGeneral disorders | 10/48 | 4/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/48 | 4/15 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 6/48 | 4/15 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/48 | 4/15 |
Includes the adult and pediatric populations
| Age, Customized(Years) | Adults | Pediatrics | Total |
|---|---|---|---|
| Age, Continuous | 49.4 ± 14.3 | 8.9 ± 4.4 | 39.8 ± 21.5 |
| Sex: Female, Male(Participants) | Adults | Pediatrics | Total |
|---|---|---|---|
| Female | 27 | 5 | 32 |
| Male | 21 | 10 | 31 |
| Race (NIH/OMB)(Participants) | Adults | Pediatrics | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 48 | 14 | 62 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Adults | Pediatrics | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 47 | 13 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index(kg/m2) | Adults | Pediatrics | Total |
|---|---|---|---|
| Mean | 30.14 ± 7.72 | 25.54 ± 25.41 | 29.03 ± 14.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Aug 2020, 35 months.
Results were first posted in Jun 2026, 5 years 10 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Primary Immunodeficiency Diseases →